Tag: genetic alterations

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsGenetic alterations

Revenium Joins FinOps Foundation as Agentic AI Spend Outpaces the Tools Built to Govern It

Share Buyback Transaction Details May 28 – June 3, 2026

Teacher confidence in AI grows, but call for more training to prepare students

Tag: genetic alterations

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us